The Importance of the Comparator in Economic Evaluations Mattias NeytHans Van Brabandt Methodological Note 11 October 2012 Pages: 913 - 916
Utility Estimation in Chronic Obstructive Pulmonary Disease Jennifer PetrilloFloortje van NootenMaureen Rutten-van MÖlken Current Opinion 11 October 2012 Pages: 917 - 932
Sample Size Determination for Cost-Effectiveness Trials Andrew R. Willan Practical Application 11 October 2012 Pages: 933 - 949
Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women Graham ScotlandNorman WaughRosemary Hollick Review Article 11 October 2012 Pages: 951 - 961
Willingness to Pay for Adverse Drug Event Regulatory Actions Jacoline BouvyJust WeemersMarc Koopmanschap Original Research Article 11 October 2012 Pages: 963 - 975
Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma Ateesha F. MohamedA. Brett HauberMaureen P. Neary Original Research Aticle 11 October 2012 Pages: 977 - 988
Rotavirus Vaccine RIX4414 (Rotarix™) Greg L. Plosker Adis Pharmacoeconomic Drug Evaluation 11 October 2012 Pages: 989 - 1009